Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318996958> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2318996958 endingPage "362" @default.
- W2318996958 startingPage "362" @default.
- W2318996958 abstract "In patients with Multiple Sclerosis (pwMS) disease-modifying therapies (DMTs) affects immune response to antigens. Therefore, post-vaccination serological assessments are needed to evaluate the effect of the vaccine on SARS-CoV-2 antibody response.We designed a prospective multicenter cohort study enrolling pwMS who were scheduled for SARS-Cov-2 vaccination with mRNA vaccines (BNT162b2, Pfizer/BioNTech,Inc or mRNA-1273, Moderna Tx,Inc). A blood collection before the first vaccine dose and 4 weeks after the second dose was planned, with a centralized serological assessment (electrochemiluminescence immunoassay, ECLIA, Roche-Diagnostics). The log-transform of the antibody levels was analyzed by multivariable linear regression.780 pwMS (76% BNT162b2 and 24% mRNA-1273) had pre- and 4-week post-vaccination blood assessments. 87 (11·2%) were untreated, 154 (19·7%) on ocrelizumab, 25 (3·2%) on rituximab, 85 (10·9%) on fingolimod, 25 (3·2%) on cladribine and 404 (51·7%) on other DMTs. 677 patients (86·8%) had detectable post-vaccination SARS-CoV-2 antibodies. At multivariable analysis, the antibody levels of patients on ocrelizumab (201-fold decrease (95%CI=128–317), p < 0·001), fingolimod (26-fold decrease (95%CI=16–42), p < 0·001) and rituximab (20-fold decrease (95%CI=10–43), p < 0·001) were significantly reduced as compared to untreated patients. Vaccination with mRNA-1273 resulted in a systematically 3·25-fold higher antibody level (95%CI=2·46–4·27) than with the BNT162b2 vaccine (p < 0·001). The antibody levels on anti-CD20 therapies correlated to the time since last infusion, and rituximab had longer intervals (mean=386 days) than ocrelizumab patients (mean=129 days).In pwMS, anti-CD20 treatment and fingolimod led to a reduced humoral response to mRNA-based SARS-CoV-2 vaccines. As mRNA-1273 elicits 3·25-higher antibody levels than BNT162b2, this vaccine may be preferentially considered for patients under anti-CD20 treatment or fingolimod. Combining our data with those on the cellular immune response to vaccines, and including clinical follow-up, will contribute to better define the most appropriate SARS-CoV-2 vaccine strategies in the context of DMTs and MS.FISM[2021/Special-Multi/001]; Italian Ministry of Health‘Progetto Z844A 5 × 1000′." @default.
- W2318996958 created "2016-06-24" @default.
- W2318996958 creator A5038703375 @default.
- W2318996958 creator A5052136474 @default.
- W2318996958 creator A5055956402 @default.
- W2318996958 date "1989-01-01" @default.
- W2318996958 modified "2023-09-26" @default.
- W2318996958 title "Scientific meeting of the Netherlands Society of Child Neurology held in Heeze, 7th of April 1989" @default.
- W2318996958 doi "https://doi.org/10.1016/0303-8467(89)90019-x" @default.
- W2318996958 hasPublicationYear "1989" @default.
- W2318996958 type Work @default.
- W2318996958 sameAs 2318996958 @default.
- W2318996958 citedByCount "0" @default.
- W2318996958 crossrefType "journal-article" @default.
- W2318996958 hasAuthorship W2318996958A5038703375 @default.
- W2318996958 hasAuthorship W2318996958A5052136474 @default.
- W2318996958 hasAuthorship W2318996958A5055956402 @default.
- W2318996958 hasConcept C126322002 @default.
- W2318996958 hasConcept C159654299 @default.
- W2318996958 hasConcept C203014093 @default.
- W2318996958 hasConcept C22070199 @default.
- W2318996958 hasConcept C2522874641 @default.
- W2318996958 hasConcept C2776036978 @default.
- W2318996958 hasConcept C2779141303 @default.
- W2318996958 hasConcept C2780640218 @default.
- W2318996958 hasConcept C2780653079 @default.
- W2318996958 hasConcept C45189115 @default.
- W2318996958 hasConcept C71924100 @default.
- W2318996958 hasConcept C83455156 @default.
- W2318996958 hasConceptScore W2318996958C126322002 @default.
- W2318996958 hasConceptScore W2318996958C159654299 @default.
- W2318996958 hasConceptScore W2318996958C203014093 @default.
- W2318996958 hasConceptScore W2318996958C22070199 @default.
- W2318996958 hasConceptScore W2318996958C2522874641 @default.
- W2318996958 hasConceptScore W2318996958C2776036978 @default.
- W2318996958 hasConceptScore W2318996958C2779141303 @default.
- W2318996958 hasConceptScore W2318996958C2780640218 @default.
- W2318996958 hasConceptScore W2318996958C2780653079 @default.
- W2318996958 hasConceptScore W2318996958C45189115 @default.
- W2318996958 hasConceptScore W2318996958C71924100 @default.
- W2318996958 hasConceptScore W2318996958C83455156 @default.
- W2318996958 hasIssue "4" @default.
- W2318996958 hasLocation W23189969581 @default.
- W2318996958 hasOpenAccess W2318996958 @default.
- W2318996958 hasPrimaryLocation W23189969581 @default.
- W2318996958 hasRelatedWork W1755302047 @default.
- W2318996958 hasRelatedWork W2564051232 @default.
- W2318996958 hasRelatedWork W2750430508 @default.
- W2318996958 hasRelatedWork W2884204030 @default.
- W2318996958 hasRelatedWork W2910349339 @default.
- W2318996958 hasRelatedWork W2977883158 @default.
- W2318996958 hasRelatedWork W2991054095 @default.
- W2318996958 hasRelatedWork W3160907605 @default.
- W2318996958 hasRelatedWork W3206160011 @default.
- W2318996958 hasRelatedWork W4320179558 @default.
- W2318996958 hasVolume "91" @default.
- W2318996958 isParatext "false" @default.
- W2318996958 isRetracted "false" @default.
- W2318996958 magId "2318996958" @default.
- W2318996958 workType "article" @default.